GlaxoSmithKline and the non-profit biotech group Aeras are to assess an experimental tuberculosis vaccine in "proof of concept" tests in Africa and India, marking a step forward in the hunt for new ways to prevent the killer disease.
The partners plan to launch a mid-stage Phase IIb clinical study in Kenya, South Africa and India next year, following successful initial tests with the GSK product, Aeras said on Wednesday.